Scholarlink

Purpose <p>The aim of this study was to determine the expression of Glypican-3(GPC-3) and AXL in hepatocellular carcinomas (HCCs).</p> Methods <p>A total of 140 patients diagnosed with HCC were included in this study. All patients had undergone radical surgery and had complete clinical information. Formalin-fixed paraffin-embedded tissue blocks of HCC from these patients were collected, and the expression levels of GPC-3 and AXL were detected by immunohistochemical (IHC) staining.</p> Results <p>Immunohistochemical analysis showed that GPC-3 and AXL were diffusely expressed&#xa0;in HCCs. The positive expression rate of&#xa0;GPC-3 was 77.1% (108/140) and that of AXL was 85.7% (120/140). Additionally,&#xa0;the proportion of cases with positive expression for either GPC-3 or AXL is 93.6%.</p> Conclusions <p>The findings of this study confirm that both GPC-3 and AXL are highly expressed in HCCs tissues, and the high co-expression rate supports the development of dual-target chimeric antigen receptor T (CAR-T) cell therapy for HCC treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

GPC-3 and AXL are essential factors and therapeutic targets for hepatocellular carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月27日

查看全文
  • Chenli Qiu,
  • Jieyi Shi,
  • Su Yan,
  • Cuisong Zhu,
  • Shuye Zhang,
  • Yanling Feng,
  • Xiaoyan Zhang,
  • Xiaowu Huang,
  • Jianqing Xu

摘要

Purpose

The aim of this study was to determine the expression of Glypican-3(GPC-3) and AXL in hepatocellular carcinomas (HCCs).

Methods

A total of 140 patients diagnosed with HCC were included in this study. All patients had undergone radical surgery and had complete clinical information. Formalin-fixed paraffin-embedded tissue blocks of HCC from these patients were collected, and the expression levels of GPC-3 and AXL were detected by immunohistochemical (IHC) staining.

Results

Immunohistochemical analysis showed that GPC-3 and AXL were diffusely expressed in HCCs. The positive expression rate of GPC-3 was 77.1% (108/140) and that of AXL was 85.7% (120/140). Additionally, the proportion of cases with positive expression for either GPC-3 or AXL is 93.6%.

Conclusions

The findings of this study confirm that both GPC-3 and AXL are highly expressed in HCCs tissues, and the high co-expression rate supports the development of dual-target chimeric antigen receptor T (CAR-T) cell therapy for HCC treatment.